ArticleAdvances in therapy2024

Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.

Ran Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.